Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon?
Cancer Cell
; 42(1): 10-12, 2024 01 08.
Article
em En
| MEDLINE
| ID: mdl-38194911
ABSTRACT
Neoadjuvant chemotherapy plus immunotherapy for triple-negative breast cancer (TNBC) is associated with improved but incomplete response. In this issue of Cancer Cell, Shiao et al. characterize longitudinal biopsies from a window of opportunity study with single-cell RNA sequencing (scRNA-seq) and spatial proteomic profiling and elucidate synergy between radiotherapy (RT) and pembrolizumab.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radioimunoterapia
/
Neoplasias de Mama Triplo Negativas
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article